Kodu・Aktsiate loetelu・Glaukos Corp

Glaukos Corp

Suletud

SektorTervishoid

184.3 -2.71

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

184.34

Max

189.43

Põhinäitajad
By Trading Economics
Sissetulek	1.4M -18M
Müük	35M 186M
Aktsiakasum	-0.14
Kasumimarginaal	-9.901
Töötajad	1,094
EBITDA	-11M -16M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+1.68% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	28. okt 2026

Turustatistika
By TradingEconomics
Turukapital	1.8B 11B
Eelmine avamishind	187.01
Eelmine sulgemishind	184.3

Uudiste sentiment

By Acuity

43%

57%

150 / 340 Pingereas Healthcare

Glaukos Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. aug 2026, 19:22 UTC

Glaukos Corp. shares are higher today amid unusually high trading volume. The stock remains significantly above its 20-day moving average.

12. aug 2026, 19:16 UTC

Glaukos Corp shares are higher today, supported by overall strength in U.S. stocks and positive quarterly results from AI sector companies.

10. aug 2026, 20:06 UTC

Glaukos Corp shares are higher today, following a broader market trend since Friday. Earlier, the stock reached a session high before pulling back.

7. aug 2026, 20:02 UTC

Glaukos Corp shares are rising in Friday's session, supported by unusually high trading volume and a steady upward trend since Thursday's close.

4. aug 2026, 19:36 UTC

Glaukos Corp shares are lower today, impacted by declines in the Health Care Equipment sub-sector. The stock pulled back after reaching an earlier high.

3. aug 2026, 20:06 UTC

Glaukos Corp shares are higher amid positive market sentiment, with the S&P 500 and Nasdaq 100 also gaining. The stock remains above its 20-day moving average.

31. juuli 2026, 19:45 UTC

News

Glaukos shares are lower today despite H.C. Wainwright raising the price target to $195 from $168. Trading volume has been unusually high.

30. juuli 2026, 21:31 UTC

News

Glaukos Corp shares are lower in after-market trading, tracking declines in the Health Care Equipment sector. UBS raised its price target to $172.

29. juuli 2026, 21:22 UTC

Social Media

News

Glaukos Corp reported record net sales of $185.6 million in Q2 2026, raising its full-year revenue guidance to $680 million to $700 million. Shares are higher in after-market trading.

28. juuli 2026, 17:46 UTC

News

Glaukos Corp shares are lower after UBS initiated coverage with a Neutral rating, overshadowing Stifel's Buy rating and $175 price target.

27. juuli 2026, 19:16 UTC

Glaukos Corp shares are lower today, despite an initial gain. Broader market trends are affected by a significant drop in oil prices.

24. juuli 2026, 19:56 UTC

Glaukos Corp. shares are trading higher today, maintaining a cumulative gain since Thursday and remaining above their 20-day moving average.

21. juuli 2026, 17:41 UTC

Glaukos Corp shares are lower today amid a decline in the Health Care Equipment sub-sector, reversing the recent trend of higher daily closes.

Võrdlus sarnastega

Hinnamuutus

Glaukos Corp Prognoos

Hinnasiht

By TipRanks

1.68% tõus

12 kuu keskmine prognoos

Keskmine 189.77 USD 1.68%

Kõrge 225 USD

Madal 153 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Glaukos Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Glaukos Corp aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

150 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.